The Pseudomonas aeruginosa exoprotein A (EPA) is an exotoxin generated by P. aeruginosa. Recombinant detoxified conjugates of EPA extracted from Pseudomonas aeruginosa by molecular biology methods have been used in clinical trials and provided safety.
Recombinant EPA is different from native exotoxin A in that an amino acid has been removed (ΔE553), making it a detoxified form of exotoxin A and preserving immunogenicity.
The malaria transmission-blocking vaccine candidate (Pfs230-EPA) is a chemically cross-conjugated combination of Pfs230 and EPA carrier proteins. Pfs230-EPA is currently undergoing clinical evaluation. The core antigen, Pfs230, is produced in yeast (Pichia pastoris), while the nontoxic carrier protein EPA is expressed in Escherichia coli (E. coli) reportedly.
Yaohai Bio-Pharma offers One-Stop CDMO Solution for Pseudomonas exotoxin A (EPA)
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
